Case Reports
doi: 10.1111/j.1651-2227.1997.tb14825.x.
Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I
Affiliations
- PMID: 9350901
- DOI: 10.1111/j.1651-2227.1997.tb14825.x
Item in Clipboard
Case Reports
Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I
Acta Paediatr.
1997 Oct.
Abstract
The effects on isoelectrofocusing patterns of serum glycoproteins were studied in a patient with CDG syndrome type I and phosphomannomutase deficiency during 3 weeks of continuous intravenous mannose infusion. Doses of 5.7 g/kg/day led to stable serum mannose levels up to 2.0 mmol/l and were well tolerated without signs of liver or renal toxicity. While most of the pathological glycoprotein patterns, including alpha1-antitrypsin, typical for CDG syndrome type I remained unchanged, mannose infusion led to a unique change of the isoelectrofocusing pattern of serum sialotransferrins with appearance of two extra bands after 3 weeks of treatment.
Similar articles
-
Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency.Eur J Pediatr. 1998 Jul;157(7):605-6. doi: 10.1007/s004310050889. Eur J Pediatr. 1998. PMID: 9686827 No abstract available.
-
Carbohydrate-deficient glycoprotein syndrome type IA (phosphomannomutase-deficiency).Biochim Biophys Acta. 1999 Oct 8;1455(2-3):155-65. doi: 10.1016/s0925-4439(99)00073-3. Biochim Biophys Acta. 1999. PMID: 10571009 Review.
-
Unsuccessful intravenous D-mannose treatment in PMM2-CDG.Orphanet J Rare Dis. 2019 Oct 22;14(1):231. doi: 10.1186/s13023-019-1213-3. Orphanet J Rare Dis. 2019. PMID: 31640729 Free PMC article.
-
Phosphomannomutase deficiency is the main cause of carbohydrate-deficient glycoprotein syndrome with type I isoelectrofocusing pattern of serum sialotransferrins.J Inherit Metab Dis. 1997 Jul;20(3):447-9. doi: 10.1023/a:1005331523477. J Inherit Metab Dis. 1997. PMID: 9266378 Clinical Trial. No abstract available.
-
Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity.Biochim Biophys Acta. 1999 Oct 8;1455(2-3):167-78. doi: 10.1016/s0925-4439(99)00072-1. Biochim Biophys Acta. 1999. PMID: 10571010 Review.
Cited by
-
A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.Mol Biol Cell. 2012 Nov;23(21):4175-87. doi: 10.1091/mbc.E12-05-0411. Epub 2012 Sep 5. Mol Biol Cell. 2012. PMID: 22956764 Free PMC article.
-
Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation.Mol Genet Genomic Med. 2013 May;1(1):32-44. doi: 10.1002/mgg3.3. Epub 2013 Mar 27. Mol Genet Genomic Med. 2013. PMID: 24498599 Free PMC article.
-
Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie).J Clin Invest. 2000 Jan;105(2):191-8. doi: 10.1172/JCI7302. J Clin Invest. 2000. PMID: 10642597 Free PMC article.
-
A good sugar, d-mannose, suppresses autoimmune diabetes.Cell Biosci. 2017 Sep 25;7:48. doi: 10.1186/s13578-017-0175-1. eCollection 2017. Cell Biosci. 2017. PMID: 29021891 Free PMC article.
-
Clinical approach to treatable inborn metabolic diseases: an introduction.J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):261-74. doi: 10.1007/s10545-006-0358-0. J Inherit Metab Dis. 2006. PMID: 16763886 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
